In liver fibrosis patients with diabetic, blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation. The gene discussed is NFKB1; the disease is Hepatic fibrosis.